RT Journal Article
SR Electronic
T1 COVID-19 convalescent plasma donors: impact of vaccination on antibody levels, breakthrough infections and reinfection rate
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.13.21260414
DO 10.1101/2021.07.13.21260414
A1 La Raja Massimo
A1 Pacenti Monia
A1 Grimaldi Ileana
A1 Boldrin Caterina
A1 Cattai Margherita
A1 Solimbergo Erica
A1 Battisti Anna
A1 Scomazzon Michele
A1 Roman Alberto
A1 Lazzaro Anna Rosa
A1 Vicari Stefano
A1 Terzariol Stefano
A1 De Silvestro Giustina
YR 2021
UL http://medrxiv.org/content/early/2021/07/19/2021.07.13.21260414.abstract
AB From April 2020 through May 2021 in Padova Province 3395 COVID-19 recovered patients were recruited as potential convalescent plasma donors and tested for SARS-CoV-2 antibodies. Since January 2021 COVID-19 vaccination campaign began in Italy, the impact of vaccination on antibody levels and suspect vaccine breakthrough infections in these subjects were investigated. Post-vaccination anti-Sars-Cov-2 antibody level in 54 previously infected subjects had an exponential increase compared to pre-vaccination level regardless of the number of vaccine doses. However after 100 days from vaccination SARS-CoV-2 antibody level tends to decline. Post-vaccination primary infections were detected in 15 cases, with 3 possible breakthrough infections after a full vaccination course. In these cases, antibody response after infection was present but weaker than the one of subjects vaccinated after natural infection. A trend toward stronger antibody response was observed with increasing distance between natural infection and vaccination. Additionally, 2 cases of asymptomatic reinfections are also discussed.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational study on convalescent plasma donors as part of the Study Protocol on Covalescent Plasma that has been approved by the Ethics Committee (EC) of the Padova University Hospital, Details on the protocol were already described elsewere https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103741/Funding StatementFunding of convalescent plasma activities was provided by the Regione del Veneto.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study is a part of the study protocol : Interventional study to evaluate the efficacy of treatment with plasma, collected from recovered COVID-19 patients (convalescent plasma or hyperimmune plasma), in patients with severe COVID-19 infection, authorised by the ethics committee of the hospital of Padua, the Italian National Blood Centre, and the Veneto regionAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the Padova transfusion department database and Padova University Hospital Microbiology and Virology service information system